Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Hideki Enokida

Kagoshima University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUL 12, 2026 · JOURNAL ARTICLE

MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening

Genes

Preclinical discovery of a synergistic drug combination in RCC cells and xenografts, supported by mechanistic CRISPR screening and validated in two cell lines, but lacking human clinical evidence and requiring translation to the clinic.

PromisingHideki Enokida Cancer Genomics and Diagnostics Yusuke Goto

Reported

Candidate synthetic lethal genes…4

RCC cell lines tested for synergy2 (786-o and A498)

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support